Compare Archer-Daniels-Midland Co (ADM) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer-Daniels-Midland Co vs BridgeBio Pharma Inc — how do they compare? Archer-Daniels-Midland Co trades at $85.02 (market cap $42.46B), while BridgeBio Pharma Inc trades at $66.51 (market cap $13.16B). The key difference: Archer-Daniels-Midland Co is far larger — about 3.2× BridgeBio Pharma Inc's market cap, and Archer-Daniels-Midland Co pays a 2.36% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Archer-Daniels-Midland Co for 73 Days and BridgeBio Pharma Inc for 63 Days on average.
| ADM | BBIO | |
|---|---|---|
Market Cap | $42.46B | $13.16B |
Volume | 3,440,954 | 2,332,775 |
Sector | Consumer Staples | Health |
52-Week High | $88.09 | $90.17 |
52-Week Low | $56.00 | $49.00 |
Typical Hold Time | 73 Days | 63 Days |
Enterprise Value | $50.70B | $14.93B |
Dividend Yield | 2.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $85.27, up 0.32% with strong technical momentum and bullish moving average signals. The stock has beaten earnings estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Analyst consensus is mixed with 33% buy ratings but a $88 price target suggesting modest upside. Recent news highlights ADM's defensive characteristics and cost-saving initiatives targeting $500-750M in savings.
Outlook remains cautiously optimistic with improving net margins projected for 2026 (2.15% vs 1.34% in 2025). Key opportunities include ethanol momentum and regenerative agriculture leadership, while risks involve commodity price volatility and ongoing revenue pressure. The stock offers defensive exposure with a reasonable valuation (P/E 24.07, P/S 0.52) amid market uncertainty.
BridgeBio Pharma (BBIO) trades at $66.18, down 3.1% with a bearish technical signal despite strong analyst support. The company shows impressive revenue growth from $502M to $713M (2025-2026) but maintains deep losses with a -97% net margin. Recent news highlights clinical successes with acoramidis showing cardiac disease reversal and Attruby driving 120% sales growth in Q2 2026.
Investment outlook balances high growth potential against substantial financial risks. While 89% of analysts recommend Buy with a $110 target representing 66% upside, the company faces execution risks with negative cash flows, $1.72B debt, and consistent earnings misses. Success depends on commercial execution and pipeline advancements to offset current unsustainable financials.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
